JSCPT 2025

Richmond Pharmacology is pleased to confirm our attendance at JSCPT 2025, the Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics, taking place in Tokyo from 5^th –6^thDecember.

‍

Representing Richmond at JSCPT 2025:

·        Dr Jörg Täubel, Chief Executive Officer

·        Dr Ulrike Lorch, Chief Medical Director

·        Stephen Wilkinson, Business Development Manager

·        Nobuo Ittetsu, Head of Japanese Volunteer Recruitment

·        Minoru Takada, Japanese Business Development Executive

We look forward to connecting with clinical and regulatory professionals to discuss Richmond’s expertise in:

·        Early-phase and first-in-human studies

·        Bridging studies between Europe and Asia

·        Gene and RNA-based therapy development

·        Pharmacokinetics, biomarkers, and trial design

·        Cross-border collaboration in complex trials

If you’re attending JSCPT 2025 and seeking a clinical development partner, arrange a meeting with one of representatives:
info@richmondpharmacology.com

Learn more: https://www.jscpt.jp/